Systematic review on definitions of intestinal ultrasound treatment response and remission in inflammatory bowel disease
- 18 January 2025
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (2)
Abstract
Background: Intestinal ultrasound (IUS) is emerging as a valuable tool to assess treatment response in inflammatory bowel disease (IBD) clinical trials. This study details how IUS defines response and remission to evaluate treatment efficacy in IBD patients. Methods: We conducted a comprehensive search of studies from 1984 to March 31, 2024, focusing on IUS use in assessing treatment efficacy in IBD. Results: A total of 51 studies were included: 31 on Crohn’s disease (CD), 12 on ulcerative colitis (UC) and 8 on IBD. Ileocolonoscopy was used as a reference standard in 53% of studies. IUS-defined response was reported in 47% of studies, with the majority (71%) using changes in bowel wall thickness (BWT) and color Doppler signals (CDS) as key indicators. IUS-defined remission was reported in 53% of studies, primarily using normalization of BWT to <3 mm and CDS to grades 0 or 1 as criteria. Ultrasonographic activity scores were used in 16% of studies, including the Bowel Ultrasound Score (BUSS) in two CD studies, the International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) in one CD study, and the Milan Ultrasound Criteria (MUC) in one UC study The remaining four studies used unvalidated scores without clear definitions of response or remission. Assessment times varied, most commonly at weeks 8–16, and at 6, 12, and 24 months. Conclusions: This systematic review reveals significant variability in IUS definitions of response and remission in IBD, highlighting the need to standardize eligibility criteria and outcome measures for IUS in IBD clinical trials.Keywords
This publication has 60 references indexed in Scilit:
- Ultrasonography Tight Control and Monitoring in Crohn’s Disease During Different Biological Therapies: A Multicenter StudyClinical Gastroenterology and Hepatology, 2022
- Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to InfliximabClinical Gastroenterology and Hepatology, 2021
- Response Assessed by Ultrasonography as Target of Biological Treatment for Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2020
- Clinical Impact of Sonographic Transmural Healing After Anti-TNF Antibody Treatment in Patients with Crohn’s DiseaseDigestive Diseases and Sciences, 2019
- Early Predictors of the Long‐term Response to Therapy in Patients With Crohn Disease Derived From a Time‐Intensity Curve Analysis After Microbubble Contrast Agent InjectionJournal of Ultrasound in Medicine, 2018
- Use of Intestinal Ultrasound to Monitor Crohn’s Disease ActivityClinical Gastroenterology and Hepatology, 2017
- A Sonographic Lesion Index for Crohn's Disease Helps Monitor Changes in Transmural Bowel Damage During TherapyClinical Gastroenterology and Hepatology, 2014
- The value of time-intensity curves obtained after microbubble contrast agent injection to discriminate responders from non-responders to anti-inflammatory medication among patients with Crohn’s diseaseEuropean Radiology, 2013
- Abdominal Sonographic Changes After Antibody to Tumor Necrosis Factor (Anti-TNF) Alpha Therapy in Crohn’s DiseaseDigestive Diseases and Sciences, 2009
- Crohn's disease and color Doppler sonography: Response to treatment and its relationship with long‐term prognosisJournal of Clinical Ultrasound, 2007